Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda's Kapidex: Can A Study On Plavix Shake Up The PPI Market?

This article was originally published in PharmAsia News

Executive Summary

Takeda could position Kapidex as the proton pump inhibitor of choice if a new clinical trial confirms its interaction profile is more agreeable than other PPI products

You may also be interested in...

BMS/Sanofi-Aventis To Study Plavix Efficacy Concerns

Genetics and concomitant PPI use are possible reasons for the anti-platelet drug’s reduced effectiveness in some patients, according to an FDA “Early Communication.”

Aetna Plans “Clinical Alert” On Plavix Use With PPIs Based On Claims Review

Aetna is developing a clinical alert for physicians and pharmacists to warn about potentially reduced effectiveness for Plavix (clopidogrel) when the antiplatelet drug is used concurrently with a proton pump inhibitor, such as Prilosec (omeprazole) or Nexium (esomeprazole)

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts